Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such
as cyclophosphamide, work in different ways to stop the growth of cancer cells either by
killing the cells or by stopping them from dividing. Vaccines made from another person's
cancer cells may help the body build an effective immune response to kill cancer cells.
Giving rituximab together with chemotherapy and vaccine therapy may kill more cancer cells
PURPOSE: This phase I/II trial is studying how well giving rituximab together with
cyclophosphamide and vaccine therapy works in treating patients with relapsed Hodgkin
lymphoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins